<DOC>
	<DOCNO>NCT01299077</DOCNO>
	<brief_summary>The purpose study observe overall satisfaction patient degenerative disc disease receive triple therapy .</brief_summary>
	<brief_title>Drug Use Survey ( DUS ) Triple Therapy ( Methycobal ( MBL ) + Myonal ( MYO ) + Non-steroidal Anti-inflammatory Drags ( NSAID ) ) Symptom Relief Lumbar DDD China</brief_title>
	<detailed_description>DDD ( lumbar disc degenerative disease ) patient prescribed triple therapy ( MBL+ MYO+ NSAIDs ) 2 week triple therapy enrol study . They ask assess overall satisfaction degree triple therapy .</detailed_description>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Inclusion criterion : 1. lumbar degenerative disc disease ( DDD ) 2. patient prescribe 2 week triple therapy Exclusion criterion : Patients meet inclusion criterion DDD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Lumbar disc degenerative disease</keyword>
	<keyword>Methycobal</keyword>
</DOC>